| (19) |
 |
|
(11) |
EP 1 674 107 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A2) |
| (48) |
Corrigendum issued on: |
|
04.10.2006 Bulletin 2006/40 |
| (43) |
Date of publication: |
|
28.06.2006 Bulletin 2006/26 |
| (22) |
Date of filing: 24.09.1999 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
Designated Extension States: |
|
AL LT LV MK RO SI |
| (30) |
Priority: |
25.09.1998 US 101828 P
24.03.1999 US 125750 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
99949913.0 / 1115417 |
| (71) |
Applicant: Cubist Pharmaceuticals, Inc. |
|
Lexington, MA 02421 (US) |
|
| (72) |
Inventors: |
|
- Oleson, Frederick B. Jr.
Concord, MA01742 (US)
- Tally, Francis P.
Lincoln, MA 01733 (US)
|
| (74) |
Representative: Vossius & Partner |
|
Siebertstrasse 4
81675 München
81675 München (DE) |
|
| |
|
|
|
Remarks: |
|
This application was filed on 30 - 03 - 2006 as a divisional application to the application
mentioned under INID code 62. |
|
(57) The invention provides methods for administering a therapeutically effective amount
of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin
administration at a dosing interval of 24 hours or greater. This long dosing interval
minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin,
which is related to daptomycin's efficacy. The invention also provides methods of
administering lipopeptide antibiotics other than daptomycin while minimizing skeletal
muscle toxicity by administering a therapeutically effective amount of the lipopeptide
antibiotic at a dosage interval that does not result in muscle toxicity. The invention
also provides methods of administering quinupristin/dalfopristin while minimizing
skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin
at a dosage interval that does not result in muscle toxicity.